Breast cancer-related lymphedema correlated with incidence of cellulitis and mortality

J Surg Oncol. 2022 Dec;126(7):1162-1168. doi: 10.1002/jso.27054. Epub 2022 Aug 12.

Abstract

Background: This study investigated breast cancer-related lymphedema (BCRL) and its correlation with the incidence of cellulitis and mortality in the National Health Insurance (NHI) database in Taiwan.

Methods: Between 2004 and 2014, the NHI database of patients with breast cancer who underwent surgical procedures, adjuvant therapies, BCRL, cellulitis, and mortality were retrospectively reviewed. Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for incidence of BCRL and cellulitis in different treatment groups. The associations of BCRL with the incidence of cellulitis and mortality were further analyzed using the Kaplan-Meier curve.

Results: Among 100 301 patients, 5464 (5.4%) developed BCRL with a median onset of 1.3 years. At a mean follow-up of 4.77 years, the incidence of cellulitis in the BCRL group (12.7%, 694/5464 patients) was significantly higher than in the no-BCRL group (2.73%, 2589/94 837 patients) (HR: 3.74; 95% CI: 3.43-4.08; p < 0.0001). At a mean follow-up of 5.77 years, the mortality rate in the cellulitis group (34.21%, 1123/3283 patients) was significantly greater than in the no-cellulitis group (16.29%, 15 804/97 018 patients) (HR: 1.17; 95% CI: 1.1-1.24; p < 0.0001).

Conclusions: BCRL had a significantly higher incidence of cellulitis and mortality.

Keywords: breast cancer; cellulitis; epidemiology; mortality.

MeSH terms

  • Breast Cancer Lymphedema* / epidemiology
  • Breast Neoplasms* / complications
  • Breast Neoplasms* / surgery
  • Female
  • Humans
  • Incidence
  • Lymphedema* / epidemiology
  • Lymphedema* / etiology
  • Lymphedema* / therapy
  • Retrospective Studies